Prophylaxis for Immunocompromised Patients
The Future in the Fight Against COVID-19 is HERE
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld™ (tixagevimab and cilgavimab). Evusheld is a potent new COVID-19 protective measure (monoclonal antibody) designed to prevent COVID-19 infection in vulnerable and immunocompromised individuals who may not mount an adequate immune response to COVID-19 vaccination.
Think you are eligable to receive Evusheld? Talk to your provider today and ask for a prescription.
What is Evusheld?
How is it Administered?
Evusheld is administered by giving two shots by intramuscular (IM) injection in the gluteal region injecting one shot right after the other.
A one hour monitoring period will follow after administration so you can expect the entire process to take 75-90 minutes.
Who is Eligable?
Learn More About EVUSHELD